These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 29220831)

  • 21. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
    Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M
    Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A multigene HIV type 1 subtype C modified vaccinia Ankara (MVA) vaccine efficiently boosts immune responses to a DNA vaccine in mice.
    Shephard E; Burgers WA; Van Harmelen JH; Monroe JE; Greenhalgh T; Williamson C; Williamson AL
    AIDS Res Hum Retroviruses; 2008 Feb; 24(2):207-17. PubMed ID: 18240963
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Correction: Induction of circulating T follicular helper cells and regulatory T cells correlating with HIV-1 gp120 variable loop antibodies by a subtype C prophylactic vaccine tested in a Phase I trial in India.
    PLOS ONE Staff
    PLoS One; 2018; 13(9):e0204476. PubMed ID: 30231061
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunogenicity and safety of the vaccinia virus LC16m8Δ vector expressing SIV Gag under a strong or moderate promoter in a recombinant BCG prime-recombinant vaccinia virus boost protocol.
    Sato H; Jing C; Isshiki M; Matsuo K; Kidokoro M; Takamura S; Zhang X; Ohashi T; Shida H
    Vaccine; 2013 Aug; 31(35):3549-57. PubMed ID: 23731631
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Correction: Safety and vaccine-induced HIV-1 immune responses in healthy volunteers following a late MVA-B boost 4 years after the last immunization.
    Guardo AC; Gómez CE; Díaz-Brito V; Pich J; Arnaiz JA; Perdiguero B; García-Arriaza J; González N; Sorzano COS; Jiménez L; Jiménez JL; Muñoz-Fernández MÁ; Gatell JM; Alcamí J; Esteban M; de Quirós JCLB; García F; Plana M;
    PLoS One; 2018; 13(4):e0195915. PubMed ID: 29634751
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Selection of recombinant fowlpox virus coexpressing HIV-1 gag-gp120 and IL-6].
    Jiang WZ; Jin NY; Li ZJ; Zhang LS; Zou XH; Wang TD
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2005 Sep; 19(3):267-70. PubMed ID: 16261213
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mucosal priming with PEI/DNA complex and systemic boosting with recombinant TianTan vaccinia stimulate vigorous mucosal and systemic immune responses.
    Huang X; Xu J; Qiu C; Ren L; Liu L; Wan Y; Zhang N; Peng H; Shao Y
    Vaccine; 2007 Mar; 25(14):2620-9. PubMed ID: 17280743
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Intranasal priming with HIV DNA vaccine and systemic boosting with recombinant vaccinia induce vigorous immune responses: experiment with mice].
    Huang XG; Xu JQ; Ren L; Qiu C; Zhang N; Liu LX; Wan YM; Peng H; Shao YM
    Zhonghua Yi Xue Za Zhi; 2006 Nov; 86(44):3109-13. PubMed ID: 17313761
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An SHIV DNA/MVA rectal vaccination in macaques provides systemic and mucosal virus-specific responses and protection against AIDS.
    Wang SW; Bertley FM; Kozlowski PA; Herrmann L; Manson K; Mazzara G; Piatak M; Johnson RP; Carville A; Mansfield K; Aldovini A
    AIDS Res Hum Retroviruses; 2004 Aug; 20(8):846-59. PubMed ID: 15320989
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A consecutive priming-boosting vaccination of mice with simian immunodeficiency virus (SIV) gag/pol DNA and recombinant vaccinia virus strain DIs elicits effective anti-SIV immunity.
    Someya K; Xin KQ; Matsuo K; Okuda K; Yamamoto N; Honda M
    J Virol; 2004 Sep; 78(18):9842-53. PubMed ID: 15331719
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sequential priming and boosting with heterologous HIV immunogens predominantly stimulated T cell immunity against conserved epitopes.
    Xu J; Ren L; Huang X; Qiu C; Liu Y; Liu Y; Shao Y
    AIDS; 2006 Nov; 20(18):2293-303. PubMed ID: 17117015
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Justification for the inclusion of Gag in HIV vaccine candidates.
    Williamson AL; Rybicki EP
    Expert Rev Vaccines; 2016 May; 15(5):585-98. PubMed ID: 26645951
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mucosal priming with replicative Tiantan vaccinia and systemic boosting with DNA vaccine raised strong mucosal and systemic HIV-specific immune responses.
    Huang X; Liu L; Ren L; Qiu C; Wan Y; Xu J
    Vaccine; 2007 Dec; 25(52):8874-84. PubMed ID: 18061316
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunogenicity and protective efficacy of heterologous prime-boost regimens with mycobacterial vaccines and recombinant adenovirus- and poxvirus-vectored vaccines against murine tuberculosis.
    You Q; Wu Y; Wu Y; Wei W; Wang C; Jiang D; Yu X; Zhang X; Wang Y; Tang Z; Jiang C; Kong W
    Int J Infect Dis; 2012 Nov; 16(11):e816-25. PubMed ID: 22921259
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clustered epitopes within the Gag-Pol fusion protein DNA vaccine enhance immune responses and protection against challenge with recombinant vaccinia viruses expressing HIV-1 Gag and Pol antigens.
    Bolesta E; Gzyl J; Wierzbicki A; Kmieciak D; Kowalczyk A; Kaneko Y; Srinivasan A; Kozbor D
    Virology; 2005 Feb; 332(2):467-79. PubMed ID: 15680412
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chimeric HIV-1 virus-like particles containing gp120 epitopes as a result of a ribosomal frameshift elicit Gag- and SU-specific murine cytotoxic T-lymphocyte activities.
    Tobin GJ; Li GH; Fong SE; Nagashima K; Gonda MA
    Virology; 1997 Sep; 236(2):307-15. PubMed ID: 9325238
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A new multi-clade DNA prime/recombinant MVA boost vaccine induces broad and high levels of HIV-1-specific CD8(+) T-cell and humoral responses in mice.
    Bråve A; Boberg A; Gudmundsdotter L; Rollman E; Hallermalm K; Ljungberg K; Blomberg P; Stout R; Paulie S; Sandström E; Biberfeld G; Earl P; Moss B; Cox JH; Wahren B
    Mol Ther; 2007 Sep; 15(9):1724-33. PubMed ID: 17579577
    [TBL] [Abstract][Full Text] [Related]  

  • 38. First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens.
    Nyombayire J; Anzala O; Gazzard B; Karita E; Bergin P; Hayes P; Kopycinski J; Omosa-Manyonyi G; Jackson A; Bizimana J; Farah B; Sayeed E; Parks CL; Inoue M; Hironaka T; Hara H; Shu T; Matano T; Dally L; Barin B; Park H; Gilmour J; Lombardo A; Excler JL; Fast P; Laufer DS; Cox JH;
    J Infect Dis; 2017 Jan; 215(1):95-104. PubMed ID: 28077588
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genital CD8+ T cell response to HIV-1 gag in mice immunized by mucosal routes with a recombinant simian adenovirus.
    de Souza AP; Haut LH; Silva R; Ferreira SI; Zanetti CR; Ertl HC; Pinto AR
    Vaccine; 2007 Jan; 25(1):109-16. PubMed ID: 16914235
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Correction: HIV-1-neutralizing antibody induced by simian adenovirus- and poxvirus MVA-vectored BG505 native-like envelope trimers.
    Capucci S; Wee EG; Schiffner T; LaBranche CC; Borthwick N; Cupo A; Dodd J; Dean H; Sattentau Q; Montefiori D; Klasse PJ; Sanders RW; Moore JP; Hanke T
    PLoS One; 2023; 18(10):e0293148. PubMed ID: 37824545
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.